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Heme oxygenase (HO)-1 and its metabolic product carbon monoxide (CO) play regulatory 
roles in acute inflammatory states. In this study, we demonstrate that CO administration is 
effective as a therapeutic modality in mice with established chronic colitis. CO administration 
ameliorates chronic intestinal inflammation in a T helper (Th)1-mediated model of murine 
colitis, interleukin (IL)-10–deficient (
 
IL-10
 
 
 
/
 
 
 
) mice. In Th1-mediated inflammation, CO 
abrogates the synergistic effect of interferon (IFN)-
 
 
 
 on lipopolysaccharide-induced IL-12 
p40 in murine macrophages and alters IFN-
 
 
 
 signaling by inhibiting a member of the IFN 
regulatory factor (IRF) family of transcription factors, IRF-8. A specific signaling pathway, 
not previously identified, is delineated that involves an obligatory role for HO-1 induction in 
the protection afforded by CO. Moreover, CO antagonizes the inhibitory effect of IFN-
 
 
 
 on 
HO-1 expression in macrophages. In macrophages and in Th1-mediated colitis, pharmacologic 
induction of HO-1 recapitulates the immunosuppressive effects of CO. In conclusion, this 
study begins to elucidate potential etiologic and therapeutic implications of CO and the 
HO-1 pathway in chronic inflammatory bowel diseases.
 
The pathogenesis of the human inflammatory
bowel diseases (IBDs) Crohn’s disease (CD)
and ulcerative colitis (UC) is complex. Genetic,
immunologic, and environmental factors are
involved in the initiation and perpetuation of
chronic intestinal inflammation (1, 2). The
role of environment in the pathogenesis of
IBD is clearly demonstrated by the epidemio-
logical observation that cigarette smoking is
protective against the development of UC (3,
4). However, the etiology of this protective
effect remains unclear. In this study, we address
one component of cigarette smoke that may
explain the clinical observation of protection
against chronic intestinal inflammation, the
gaseous molecule carbon monoxide (CO).
CO has antiinflammatory effects in murine
models of sepsis, postoperative ileus, and organ
xenotransplantation (5–7). In contrast to the
accumulating evidence of a regulatory role for
CO in acute tissue injury, little is known regard-
ing the physiological role of CO in mucosal
immunity and chronic inflammation. Mamma-
lian cells generate CO endogenously as a product
of heme degradation by the heme oxygenase
(HO) enzymes (8). Two primary isoforms of
HO exist: HO-1 is ubiquitously expressed and
highly inducible, whereas HO-2 is constitutively
expressed primarily in the central nervous system
and vascular beds (9). HO-1 is induced by a
variety of agents causing oxidative stress and
inflammation (10). HO-1 knockout (
 
hmox
 
 
 
/
 
 
 
)
mice as well as one reported case of an HO-1–
deficient human patient exhibited increased
inflammatory indices, including leukocytosis
and thrombocytosis (11, 12).
In acute inflammation, CO-mediated pro-
tection is associated with inhibition of the in-
flammatory cytokine response. For example,
macrophages exposed to LPS in the presence
of CO produced significantly less TNF (13).
In addition, CO significantly increased LPS-
induced accumulation of the antiinflammatory
cytokine IL-10. Imbalances in proinflammatory
and antiinflammatory cytokines play a major
role in the pathogenesis of IBD (14). Recent
studies have emphasized the importance of the
cytokine subunit IL-12 p40. IL-12 p40, ex-
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pressed in macrophages and dendritic cells, plays a central role
in bridging innate and adaptive immune responses (15, 16).
IL-12 and IL-23 are heterodimeric cytokines composed of
this common p40 subunit and the p35 and p19 subunit, re-
spectively. IL-12 and IL-23 are involved in the induction and
maintenance of Th1 responses and chronic inflammation (17,
18). Anti–IL-12 p40 antibodies ameliorate colitis in Th1-
mediated murine models, such as 
 
IL-10
 
 
 
/
 
 
 
 mice (19), and are
currently under clinical evaluation in CD (20). Accordingly,
akin to acute tissue injury, changes in cytokine profile in-
duced by CO may be beneficial in chronic inflammation.
In this study, we demonstrate that CO administration
ameliorates chronic intestinal inflammation in a Th1-medi-
ated model of murine colitis, 
 
IL-10
 
 
 
/
 
 
 
 mice. Mechanisti-
cally, CO abrogates the synergistic effect of IFN-
 
 
 
 on LPS-
induced IL-12 p40 in murine macrophages and alters IFN-
 
 
 
signaling by inhibiting the IFN regulatory factor (IRF),
IRF-8. A specific signaling pathway is delineated that in-
volves an obligatory role for HO-1 induction in the protec-
tion afforded by CO. Accordingly, pharmacologic induction
of HO-1 recapitulates the immunosuppressive effects of CO
in macrophages and in vivo. Therefore, CO and HO-1 have
immunomodulatory roles in chronic intestinal inflammation,
and this pathway may have relevance in the human IBDs.
 
RESULTS
CO exposure ameliorates Th1-mediated chronic 
murine colitis
 
The immunomodulatory effects of CO were studied in a
murine model of Th1-mediated chronic intestinal inflamma-
tion, 
 
IL-10
 
 
 
/
 
 
 
 mice. Mice were exposed to 250 ppm CO
from 8 to 12 wk of age (
 
n 
 
 
 
 12) and compared with a con-
trol group exposed to ambient air (
 
n
 
 
 
 
 
 8). Because hypoxia
can become a confounding factor at carboxyhemoglobin
levels of 
 
 
 
20% (13, 21), carboxyhemoglobin levels of CO-
exposed mice were determined and were uniformly 
 
 
 
14%
(as well as in all subsequent in vivo experiments). Assessment
of histologic improvement in 
 
IL-10
 
 
 
/
 
 
 
 mice can be prob-
lematic because of incomplete penetrance and the segmental,
patchy pattern of colitis. Therefore, histological results are
depicted in two different ways. First, 20 random fields dis-
tributed over the entire length of colon for each mouse were
graded by a pathologist blinded to the treatment group using
a standard scoring system (22). Results are presented as the
sum total of four averaged scores from five regions of the
large intestine. CO-exposed mice demonstrate a 60% im-
provement in histological scores compared with air-exposed
mice (Fig. 1 B, left). To represent the spectrum of histologi-
cal changes in individual mice, results are also presented as
the percentage of 20 fields per mouse that demonstrate no
histological inflammation (colitis score of 0), mild to moder-
ate inflammatory changes (colitis score of 1 and 2), and se-
vere inflammation (colitis score of 3 and 4). In the CO-
exposed group, compared with air-exposed 
 
IL-10
 
 
 
/
 
 
 
 mice,
significantly more colonic fields demonstrate no evidence
of histologic inflammation, and likewise significantly fewer
fields demonstrated inflammatory changes (Fig. 1 B, right).
Furthermore, CO-exposed 
 
IL-10
 
 
 
/
 
 
 
 mice show less weight
loss compared with air-exposed controls (1.48 
 
 
 
 1.27 vs.
0.22 
 
 
 
 1.35 grams; P 
 
 
 
 0.05).
Figure 1. CO abrogates colitis in IL-10 /  mice. IL-10 /  mice 
were housed in ambient air (n   8) or a chamber maintaining a constant 
concentration of 250 ppm CO (n   12) from 8 through 12 wk of life. 
(A) Representative hematoxylin and eosin staining and histologic colitis of 
IL-10 /  colonic tissue. Left, ambient air; right, CO-treated. (B) Colitis 
scores were significantly decreased in CO-exposed mice compared with 
control mice. *, P   0.01; **, P   0.001. (C) Colitis scores of 8-wk-old 
IL-10 /  mice fed piroxicam-supplemented chow for 5 d and then exposed 
to ambient air or 250 ppm CO for 2 wk. *, P   0.01; **, P   0.001. 
(D) Spontaneous IL-12 p40 and TNF protein secretion was determined 
in 24-h supernatants from intestinal explants from CO- and air-exposed 
IL-10 /  mice. Each result represents the mean   SD of triplicate assays 
and is representative of three independent experiments. (E) 10-wk-old 
IL-10 /  mice were exposed to 250 ppm CO or ambient air for 1, 4, or 7 d 
(four mice per group). Intestinal explants were cultured for 24 h, and 
spontaneous IL-12 p40 and p70 as well as IL-23 protein secretion was 
determined. Results represent the mean of triplicate samples of pooled 
intestinal explant cultures from each group. 
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Importantly, these results suggest that CO exposure
ameliorates preexisting colitis. To conclusively demonstrate
this point, we tested the therapeutic effects of CO adminis-
tration in a model of severe, chronic intestinal inflammation
with 100% penetrance. Severe colitis was induced in 8-wk-
old 
 
IL-10
 
 
 
/
 
 
 
 mice by feeding 200 ppm piroxicam-supple-
mented chow for 5 d. In the original description of this
model (23), piroxicam administration for 10 d to 4–6-wk-
old 
 
IL-10
 
 
 
/
 
 
 
 mice resulted in severe colitis in 100% of mice
that persisted upon withdrawal of piroxicam from the diet.
Due to 100% mortality within 7 d of piroxicam feeding in
our facility (not depicted), the protocol was accordingly
modified. After removal of piroxicam from the diet, mice
were exposed to either CO or ambient air (
 
n
 
 
 
 
 
 5 mice
each) for 2 wk. CO exposure significantly ameliorated es-
tablished, severe colitis as determined by improved histo-
logic parameters (Fig. 1 C). In this model, piroxicam repre-
sents an initiating factor for chronic inflammation rather
than the cause per se. Severe inflammation persists after
withdrawal of piroxicam, and although piroxicam may
cause acute gastrointestinal injury, 8-wk-old wild-type
C57Bl/6 mice treated with piroxicam for 5 d do not dem-
onstrate intestinal inflammation 2 wk after withdrawal (not
depicted; reference 23).
To determine whether CO exposure affects mucosal in-
flammatory cytokine production in 
 
IL-10
 
 
 
/
 
 
 
 mice, sponta-
neous IL-12 p40 and TNF levels were measured in super-
natants from colonic mucosal tissue. Intestinal explants of
 
IL-10
 
 
 
/
 
 
 
 mice exposed to CO in vivo for 4 wk express signif-
icantly less IL-12 p40 and TNF compared with explants from
air-exposed mice (Fig. 1 D). Kinetics of inhibition of intesti-
nal IL-12 p40 by CO was next determined. 
 
IL-10
 
 
 
/
 
 
 
 mice
were exposed to 250 ppm CO for 1, 4, and 7 d. Intestinal
secretion of IL-12 p40 was measured in intestinal explant
culture and compared with values obtained from air-exposed
 
IL-10
 
 
 
/
 
 
 
 mice. Intestinal IL-12 p40 is inhibited after 4 and
7 d of CO exposure, but not after 1 d (Fig. 1 E). Importantly,
at 4 and 7 d, significant histological improvement was not
demonstrated between the groups (not depicted), suggesting
that CO inhibits IL-12 p40 expression before resolution of
intestinal inflammatory infiltrates. IL-12 p40 heterodimerizes
with p35 or p19 to produce biologically active IL-12 p70 or
IL-23, respectively. Intestinal secretion of IL-12 p70 and IL-
23 was measured in CO-treated and air-exposed 
 
IL-10
 
 
 
/
 
 
 
mice. CO strongly inhibits IL-12 p70 at days 4 and 7,
whereas a less significant inhibitory effect on intestinal IL-23
secretion is demonstrated (Fig. 1 E).
 
CO alters IFN-
 
 
 
 signaling in macrophages
 
CO inhibits synergistic activation of IL-12 p40 protein se-
cretion and mRNA expression by LPS/IFN-
 
 
 
 in murine 
macrophages.
 
As IL-12 p40 protein secretion was reduced
in intestinal explants of CO-exposed 
 
IL-10
 
 
 
/
 
 
 
 mice, the
molecular effects of CO on IL-12 p40 expression were in-
vestigated in murine BM-derived macrophages. Because
IFN-
 
 
 
 is important for optimal expression of LPS-induced
IL-12 p40 secretion, macrophages were stimulated with LPS
or LPS/IFN-
 
 
 
. Exposure of cells to CO at 250 ppm inhibits
synergistic activation of IL-12 p40 protein production (Fig. 2
A) and mRNA expression (Fig. 2 B) by LPS/IFN-
 
 
 
. A dose-
dependent inhibition of LPS/IFN-
 
 
 
–induced IL-12 p40
mRNA and protein at CO concentrations of 0, 50, 100, and
250 ppm was observed (not depicted). Furthermore, CO in-
hibits LPS/IFN-
 
 
 
–induced IL-12 p40 protein and mRNA
expression across a range of LPS concentrations (10–1,000
ng/ml; not depicted). Next, the effects of CO on biologically
active IL-12 p70 and IL-23 were studied. Again, the main ef-
fect of CO was inhibition of the synergistic induction of
IL-12 p70 by LPS/IFN-
 
 
 
. IFN-
 
 
 
 does not augment LPS-
induced IL-23 secretion, and CO did not inhibit IL-23 acti-
vation (Fig. 2 C). Similar results were obtained using murine
splenocytes and peritoneal macrophages (not depicted).
 
CO inhibits LPS/IFN-
 
 
 
–induced IL-12 p40 promoter ac-
tivity and activates an IFN-stimulated response element 
(ISRE).
 
IL-12 p40 is transcriptionally regulated through a
number of cis-acting elements that are responsive to bacterial
Figure 2. CO inhibits LPS/IFN- –induced IL-12 p40 expression 
in murine macrophages and alters IFN-  signaling. (A) BM-derived 
murine macrophages were cultured in 250 ppm CO or ambient air. After 
activation with 1  g/ml LPS and/or 10 ng/ml IFN- , IL-12 p40 protein was 
assayed from supernatants at 24 h. (B) IL-12 p40 mRNA expression was 
determined at 4 h by real-time RT-PCR. (C) IL-12 p70 and IL-23 protein 
secretion was assayed by ELISA at 24 h. (D) J774 murine macrophages 
were transiently transfected with an IL-12 p40 promoter-luciferase 
reporter construct or (E) a multimerized ISRE-luciferase reporter plasmid. 
Cells were cultured in 250 ppm CO after the addition of 1  g/ml LPS or 
1  g/ml LPS plus 10 ng/ml IFN-  for 18 h. Results are expressed as relative 
light units normalized to activity from a cotransfected constitutively 
active  -galactosidase reporter plasmid. 
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products and IFN-
 
 
 
 (15). To study inhibition of LPS/IFN-
 
 
 
–induced IL-12 p40 transcription by CO, IL-12 p40 pro-
moter activity was determined in the J774 murine macro-
phage cell line. J774 cells were transiently transfected with a
murine IL-12 p40 promoter fused to a luciferase reporter
gene and then activated with IFN-
 
 
 
 plus LPS in the pres-
ence or absence of CO at 250 ppm for 24 h. CO selectively
inhibits IL-12 p40 promoter activity synergistically induced
by LPS/IFN-
 
 
 
 (Fig. 2 D).
IFN-
 
 
 
 signaling induces gene transcription through
DNA motifs, designated ISRE, found in promoters of IFN-
 
 
 
–inducible genes that bind the IRF family of transcription
factors. Therefore, we determined whether CO modulates
LPS/IFN-
 
 
 
 activation of a promoter that contains a consen-
sus ISRE. J774 cells were transiently transfected with a plas-
mid containing a multimerized consensus ISRE fused to a
luciferase reporter gene. Cells exposed to 250 ppm CO and
activated with LPS/IFN-
 
 
 
 showed significantly augmented
ISRE reporter activity (Fig. 2 E).
 
CO selectively inhibits IRF-8 protein expression. To
summarize, for IL-12 p40, CO antagonizes IFN-  responses,
whereas for an ISRE, CO augments IFN- –induced activity.
Accordingly, we hypothesized that CO affects gene transcrip-
tion through IRF family members. A logical target is IRF-8.
IRF-8 is an important transcription factor for IL-12 p40 regu-
lation and promoter activation (16). Moreover, IRF-8 is a
transcriptional repressor through an ISRE. J774 cells were
stimulated with LPS/IFN-  and cultured either in ambient air
or 250 ppm CO for 4, 6, and 12 h. As determined by Western
immunoblot in nuclear extracts, CO inhibits LPS/IFN- –
activated IRF-8 protein expression compared with cells exposed
to air (Fig. 3 A). Similar results are observed in murine spleno-
cytes (Fig. 3 B). To determine whether CO inhibition of
IRF-8 was specific, other transcription factors activated by
IFN-  were evaluated. CO exposure did not inhibit IRF-1,
IRF-4, and phosphorylated STAT3 in LPS/IFN- –activated
J774 cells (Fig. 3 A) or murine splenocytes (Fig. 3 B). Simi-
larly, activated STAT1 (phosphorylated STAT1) and IRF-2
expression, induced by LPS/IFN-  in murine macrophages,
were not affected by CO (not depicted).
To provide evidence that IL-12 p40 inhibition by CO is
directly mediated through IRF-8, IRF-8 was expressed in
BM-derived macrophages by retroviral transduction using a
derivative of the Moloney murine leukemia virus vector,
pMMP412. 48 h after retroviral transduction, cells were ex-
posed to 250 ppm CO or ambient air and activated with LPS
with or without IFN-  for 24 h. As expected, IRF-8–trans-
duced macrophages produce higher levels of LPS-stimulated
IL-12 p40 protein (Fig. 3 C). Importantly, in IRF-8–trans-
duced BM-derived macrophages, the inhibitory effects of
CO on LPS/IFN- –stimulated IL-12 p40 is abrogated,
compared with control virus–transduced cells (Fig. 3 C).
Collectively, these data demonstrate that CO inhibits LPS/
IFN- –induced IL-12 p40 expression through IRF-8.
CO inhibition of IL-12 p40 is independent of IL-10, 
MKK3, and nitric oxide (NO). The effects of CO on
inflammatory cytokine signaling may encompass multiple
pathways (13, 24). IL-10 has numerous antiinflammatory ac-
tivities, perhaps the most important of which is its ability to
strongly inhibit IL-12 p40 (25). Therefore, increases in LPS-
induced IL-10 expression in CO-exposed macrophages may
explain inhibition of IL-12 p40 production. To test this pos-
sibility, IL-10 /  BM-derived macrophages were activated
with LPS/IFN-  in the presence or absence of CO. CO ex-
posure inhibits IL-12 p40 protein production (Fig. 4 A) and
mRNA expression (Fig. 4 B) induced by LPS and LPS/IFN- .
Similar results were found in IL-10 /  splenocytes, and CO
also inhibits bioactive IL-12 p70 secretion (not depicted).
CO also inhibits IRF-8 protein expression in IL-10 /  mac-
rophages (Fig. 4 C).
In a sepsis model, induction of IL-10 by CO was medi-
ated by the MAPK signaling pathway MKK3/p38. p38 acti-
vation has been correlated with increased IL-12 p40 expres-
sion (13). Therefore, we investigated whether the inhibitory
effects of CO on IL-12 is mediated through the MKK3/p38
Figure 3. CO selectively inhibits LPS/IFN- –induced IRF-8 in murine 
macrophages. (A) Western blot analysis of IRF family members in J774 
murine macrophages. Lanes 1–4 represent ambient air-exposed cells, and 
lanes 5–8 represent cells exposed to CO. Lanes 1 and 5, unstimulated; lanes 
2 and 6, LPS/IFN-  stimulated for 4 h; lanes 3 and 7, LPS/IFN-  stimulated 
for 6 h; lanes 4 and 8, LPS/IFN-  stimulated for 12 h; lane 9, nuclear 
extracts of RAW264.7 cells stimulated with LPS/IFN- . (B) Western blot 
analysis of IRF family members or phospho–STAT-3 in murine splenocytes. 
Lane 1, unstimulated; lanes 2 and 3 stimulated with LPS/IFN-  for 8 h in 
the absence or presence of 250 ppm CO, respectively. (C) BM-derived mac-
rophages were transduced with retrovirus IRF-8 or empty virus as control. 
48 h after infection, cells were seeded in 24-well plates at 106 cells/ml, 
stimulated with 1  g/ml LPS or LPS and 10 ng/ml IFN- , and incubated for 
24 h in the absence or presence of 250 ppm CO. Supernatants were then 
collected, and IL-12 p40 protein secretion was measured by ELISA. IRF-8 
protein expression was determined by Western blot in nuclear extracts 
from unstimulated retrovirus IRF-8–infected macrophages and control 
virus–infected cells (inset). Each result is representative of three indepen-
dent experiments.JEM VOL. 202, December 19, 2005 1707
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axis. In BM-derived macrophages from MKK3 /  mice,
CO inhibits LPS/IFN- –activated IL-12 p40 and p70 secre-
tion (not depicted). Therefore, CO inhibition of LPS/IFN-
 –stimulated IL-12 p40 expression is independent of IL-10
and the p38 MAPK pathway.
We have previously shown that NO inhibits IL-12 p40
transcription (26). Furthermore, CO induces NO in hepato-
cytes (27). To test whether NO mediates inhibition of IL-12
p40 by CO, BM-derived macrophages from inos /  mice
were incubated in 250 ppm CO and stimulated with LPS or
LPS/IFN- . CO inhibits LPS/IFN- –stimulated IL-12 p40
and p70 secretion in inos /  macrophages (not depicted),
suggesting that the inhibition of IL-12 expression by CO is
inducible NO synthase (iNOS) independent.
CO-mediated modulation of IFN-  signaling requires HO-1
In hepatocytes, CO up-regulates HO-1 activity, and inhibi-
tion of HO-1 abrogates the protective effects of CO in a
model of acute liver failure (27). To determine whether
HO-1 is required for downstream effects of CO on IFN- 
signaling, BM-derived macrophages were obtained from
hmox /  mice. Interestingly, in hmox /  macrophages, inhi-
bition of LPS/IFN- –induced IL-12 p40 production by ex-
ogenous CO exposure is completely abrogated (Fig. 5 A),
fostering the hypothesis that the immunomodulatory effects
of CO are mediated by HO-1 or one of its other metabolic
products. In support of this hypothesis, in BM-derived mac-
rophages, the selective HO-1 inhibitor tin protoporphyrin
(SnPP) abrogates the inhibitory effect of exogenous CO on
LPS/IFN- –stimulated IL-12 p40 secretion in a concentra-
tion-dependent manner (Fig. 5 B).
Expression of iNOS is up-regulated in macrophages by
LPS/IFN-  (28). Importantly, similar to IL-12 p40, the murine
iNOS promoter is regulated by IRF-8 (28). Therefore, we
studied whether CO would alter IFN- –induced accumula-
tion of the end product of iNOS activity, NO. In murine BM-
derived macrophages, CO inhibits LPS/IFN- –stimulated NO
production (measured by nitrite production; not depicted). CO
also inhibits LPS/IFN- –stimulated iNOS mRNA expression
(not depicted). These results lend further credence to the ob-
servation that CO alters IFN-  signaling through specific inhi-
bition of IRF-8. Furthermore, pharmacologic inhibition of
HO-1 by SnPP abrogates the inhibitory effect of CO on LPS/
IFN- –stimulated NO production (not depicted), suggesting
Figure 4. CO inhibits LPS/IFN- –induced IL-12 p40 expression 
independent of IL-10. (A) BM-derived macrophages from IL-10 /  mice 
were cultured in 250 ppm CO or ambient air before activation with 1  g/ml 
LPS or 1  g/ml LPS plus 10 ng/ml IFN- . IL-12 p40 protein was assayed 
from supernatants at 24 h. (B) IL-12 p40 mRNA expression was determined 
at 4 h by real-time RT-PCR. Each result represents the mean   SD of 
triplicate assays and is representative of three independent experiments. 
(C) IL-10 /  BM-derived macrophages were either unstimulated or activated 
with LPS/IFN-  for 8 h in the absence or presence of 250 ppm CO. IRF-8 
protein expression was determined in nuclear extracts by Western blot 
(representative of three experiments).
Figure 5. Inhibition of LPS/IFN- –induced IL-12 p40 production 
by CO is HO-1 dependent. (A) BM-derived macrophages from hmox /  
mice were activated with 1  g/ml LPS and 10 ng/ml IFN-  in the presence 
or absence of 250 ppm CO. IL-12 p40 protein was measured in superna-
tants at 24 h. Each result represents the mean   SD of triplicate assays 
and is representative of three independent experiments. (B) BM-derived 
murine macrophages were cultured with or without an HO-1 inhibitor 
(SnPP) for 1 h before stimulation with LPS/IFN-  in the presence or absence 
of 250 ppm CO. Results are presented as percent inhibition of LPS/IFN- –
stimulated IL-12 p40 secretion by CO at 24 h. (C) BM-derived macrophages 
were incubated with 25 and 50  M of the HO-1 inhibitor SnPP for 1 h 
before stimulation with 1  g/ml LPS plus 10 ng/ml IFN-  in the absence 
or presence of 250 ppm CO for 8 h. IRF-8 protein expression in nuclear 
extracts was determined by Western blot. This result is representative of 
three independent experiments. (D) BM-derived macrophages from 
hmox /  mice were stimulated with 1  g/ml LPS plus 10 ng/ml IFN-  in 
the absence or presence of 250 ppm CO for 8 h. IRF-8 in nuclear extracts 
was determined by Western blot. This result is representative of three 
independent experiments.CARBON MONOXIDE AMELIORATES CHRONIC MURINE COLITIS | Hegazi et al. 1708
that, similar to IL-12 p40, CO inhibits iNOS activity and/or
expression through an HO-1–dependent pathway.
To demonstrate that IRF-8 is downstream of HO-1 in
this CO inhibitory pathway, IRF-8 expression was evaluated
in the presence of an HO-1 inhibitor and in hmox /  mac-
rophages. Pharmacologic inhibition of HO-1 with SnPP
(Fig. 5 C) abrogates the inhibitory effect of CO on LPS/
IFN- –stimulated IRF-8 protein expression in BM-derived
macrophages. Likewise, in BM-derived hmox /  macro-
phages, CO does not inhibit LPS/IFN- –stimulated IRF-8
expression (Fig. 5 D). These results further substantiate that
CO alters IFN-  signaling and abrogates IL-12 p40 expres-
sion through IRF-8, and that these effects require HO-1.
To begin to determine mechanistically how HO-1 me-
diates the described actions of CO, we tested whether CO
alters HO-1 expression. HO-1 protein expression was de-
termined in cellular extracts from murine BM-derived
macrophages stimulated with LPS, IFN- , or both in the
presence or absence of CO. IFN-  inhibits basal and
LPS-induced HO-1 protein expression in murine macro-
phages, and CO antagonizes the inhibitory effects of IFN-  on
HO-1 expression (Fig. 6 A). Likewise, HO-1 mRNA expres-
sion is inhibited by IFN- , and the inhibitory effect is abro-
gated by CO (not depicted). To determine whether CO
alters HO-1 expression in vivo, intestinal sections from CO-
exposed  IL-10 /  mice and air-exposed IL-10 /  mice,
matched for histologic colitis severity, were evaluated for
HO-1 expression. Increased immunoreactivity for HO-1 in
the intestinal epithelia and increased numbers of lamina pro-
pria cells with HO-1 immunoreactivity are observed in CO-
exposed mice (Fig. 6 B). Thus, CO abrogates the inhibitory
effect of IFN-  on HO-1 expression in macrophages and in-
duces intestinal HO-1 in vivo in IL-10 /  mice.
Therefore, genetic and pharmacologic experiments dem-
onstrate that CO acts through an HO-1–dependent path-
way, and we hypothesized that another metabolic product of
HO-1 may mediate the immunomodulatory effects of CO.
Biliverdin has been recently described to alter T cell signal-
ing and decrease IFN-  production (29). BM-derived mu-
rine macrophages were treated with biliverdin at concentra-
tions of 10 to 100  M for 2 h before activation with LPS or
LPS/IFN- . Biliverdin does not inhibit IL-12 p40 mRNA
expression or protein production (not depicted). Therefore,
the effects of CO and HO-1 on IL-12 expression are not
mediated by biliverdin in this experimental system.
HO-1 induction recapitulates the immunomodulatory 
effects of CO
BM-derived macrophages were treated with the HO-1 in-
ducer hemin and then stimulated with LPS or LPS/IFN- .
Pretreatment with hemin inhibits LPS/IFN- –stimulated
IL-12 p40 secretion in a concentration-dependent manner
(Fig. 7 A). Furthermore, hemin dose dependently induces
HO-1 and inhibits IRF-8 protein expression (Fig. 7 B). To
study HO-1 induction in vivo, hemin was administered by
i.p. injection (25 mg/kg) twice weekly for 2 wk to 10-wk-
old  IL-10 /  mice. In vivo administration of hemin in-
creased intestinal HO-1 protein expression (Fig. 8 A). Histo-
Figure 6. CO abrogates the inhibitory effect of IFN-  on basal and 
LPS-induced HO-1 protein expression in macrophages and up-regulates 
intestinal HO-1 expression in IL-10 /  mice. (A) BM-derived macrophages 
were stimulated with 1  g/ml LPS, 10 ng/ml IFN- , or both for 8 h and 
cultured in the presence or absence of CO. Western blotting was performed 
on whole cell extracts for HO-1 protein expression. Results are representative 
of three independent experiments (B) Immunohistochemical analysis of 
intestinal HO-1 protein expression in CO-treated and control air–exposed 
IL-10 /  mice (exposed from 8 to 12 wk of age). Depicted intestinal sections 
were matched for similar histologic colitis activity.
Figure 7. HO-1 induction inhibits LPS/IFN- –activated IRF-8 and 
IL-12 p40 expression in macrophages. (A) BM-derived macrophages 
were cultured with or without the HO-1 inducer hemin for 3 h before 
stimulation with 1  g/ml LPS or 1  g/ml LPS plus 10 ng/ml IFN- . IL-12 
p40 protein was measured in 24-h supernatants. Results are presented 
as percent inhibition of LPS/IFN- –stimulated IL-12 p40 secretion by 
hemin and represent the mean   SD from three independent experiments. 
(B) BM-derived macrophages were cultured with or without hemin for 
3 h before stimulation with LPS/IFN-  for 8 h. IRF-8 and HO-1 protein 
expression was measured in 20  g of nuclear extract by Western blot. 
Equal loading of lanes was confirmed by equivalent expression of GAPDH 
between lanes (not depicted). Results are representative of three indepen-
dent experiments.JEM VOL. 202, December 19, 2005 1709
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logic evaluation of colitis was compared with a control
group treated i.p. with vehicle alone (n   7 per group).
Hemin-treated IL-10 /  mice demonstrate improved histol-
ogy (Fig. 8 B) and less weight loss (not depicted) than vehi-
cle-treated controls. Similar histological improvement was
observed in IL-10 /  mice treated with another HO-1 in-
ducer, cobalt protoporphyrin (CoPP; 5 mg/kg i.p. twice
weekly for 2 wk; n   7 per group; Fig. 8 C). Furthermore,
decreased IL-12 p40 expression is demonstrated in intestinal
explant cultures from hemin- and CoPP-treated IL-10 / 
mice compared with vehicle treated mice (Fig. 8 D). These
results suggest a novel pathway where HO-1 mediates the
antiinflammatory properties of CO. Collectively, cell culture
and in vivo data demonstrate a potent immunomodulatory
role for CO and HO-1 in chronic mucosal inflammation.
DISCUSSION
In summary, CO exposure at low concentrations ameliorates
Th1-mediated chronic murine colitis. Mechanistically, the
effects of CO upon macrophage activation were studied, fo-
cusing on the regulation of the IL-12 p40 gene, important in
the pathogenesis of Th1-mediated colitis. In murine mac-
rophages, CO inhibits the synergistic activation of IL-12 p40
and iNOS by LPS/IFN-  through selective inhibition of
IRF-8. Furthermore, the immunologic effects of CO require
HO-1. CO induces HO-1 expression, again, through antag-
onism of IFN-  signaling. In the absence of functional HO-1,
the inhibitory action of CO on IRF-8 and IL-12 p40 expres-
sion is lost. As proof of this concept, pharmacologic HO-1
induction with hemin and CoPP recapitulates the effects of
CO in cells and in vivo. In macrophages, HO-1 inducers in-
hibit LPS/IFN- –induced IRF-8 and IL-12 p40 expression,
and in IL-10 /  mice, HO-1 inducers ameliorate colitis.
Despite the classification of CO as a toxic entity, lethal to
aerobic life and one of the primary pollutants in industrial
society, CO has recently emerged as a potent immunomod-
ulatory entity. In the gastrointestinal tract, CO has been
studied as a gaseous enteric neurotransmitter and as such is
critically involved in smooth muscle membrane potential
and ileal contractility (30). Recently, in a murine model of
acute mucosal injury (dextran sodium sulfate–induced coli-
tis), the HO-1 inducer CoPP modestly ameliorated inflam-
matory changes, but CO had no effect (29). In addition,
pharmacologic inhibition of HO-1 exacerbated TNBS-
induced acute colitis in rats (31). This study is the first to
suggest an antiinflammatory role for CO in chronic intestinal
inflammation and the first to investigate the HO-1 pathway
in established chronic intestinal inflammation.
We directed our mechanistic analyses toward the obser-
vation that CO ameliorated Th1-mediated chronic intestinal
inflammation in IL-10 /  mice. In murine macrophages,
CO affects IFN-  signaling and IL-12 p40 expression. The
IRF family member IRF-8 is specifically expressed in he-
matopoietic cells and is induced by IFN-  (as well as LPS) at
the protein and mRNA level in macrophages (32). IRF-8 / 
macrophages display selective impairment of IL-12 p40 ex-
pression. We have recently demonstrated a functional com-
posite DNA binding element in the murine IL-12 p40 pro-
moter that binds IRF family members, most notably IRF-8
(16). In different biologic situations, IRFs may serve as tran-
scriptional activators or repressors (33). IRF-8 and IRF-2
have been demonstrated to inhibit IRF-1–mediated activa-
tion of promoters with a consensus ISRE, but IRF-8 is
clearly involved in activation of the IL-12 p40 promoter.
Therefore, our results suggest that CO exerts immunomod-
ulatory effects through inhibition of IRF-8, thereby altering
the ratio of IRF family members induced by IFN-  in mac-
rophages. Our finding that CO inhibits the synergistic acti-
vation of NO production by IFN-  and LPS supports this
hypothesis. The iNOS promoter contains a novel ISRE
where IRF-8 plays an activating role (28).
In hmox /  macrophages, CO does not inhibit IL-12 p40
and IRF-8 expression. In addition, pharmacologic induction
of HO-1 inhibits LPS/IFN- –induced IL-12 p40 and IRF-8
Figure 8. HO-1 induction ameliorates colitis in IL-10 /  mice. 
(A) 10-wk-old IL-10 /  mice were treated with i.p. injection of hemin 
(25 mg/kg twice weekly for 2 wk), and control mice were treated i.p. with 
PBS vehicle (n   7 per group). Induction of intestinal HO-1 in hemin-
treated mice was detected by Western blot (top). Colitis scores were 
significantly lower in the hemin-treated mice. *, P   0.01; **, P   0.001. 
Histologic improvement in colitis is presented as average colitis scores 
(middle) and percent of histologic field that demonstrate no inflammation, 
mild to moderate inflammation, and severe inflammation as described in 
Results (bottom). (B) 10-wk-old IL-10 /  mice were treated with i.p. injection 
of CoPP (5 mg/kg twice weekly for 2 wk), and control mice were treated 
i.p. with PBS vehicle (n   7 per group). Colitis scores, presented as in A, 
were significantly lower in CoPP-treated mice. *, P   0.01; **, P   0.001. 
(C) Intestinal explants from vehicle-, hemin-, or CoPP-treated IL-10 /  
mice were cultured for 24 h for measurement of spontaneous IL-12 p40 
secretion by ELISA. Results represent mean   SD of triplicate assays of 
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in wild-type macrophages. Therefore, CO may act primarily
through induction of HO-1. Our findings using pharmaco-
logic inducers and inhibitors of HO-1 parallel observations in
a model of liver failure where inhibition of HO-1 activity in
hepatocytes resulted in a loss of the protective effects con-
ferred by CO (27). The precise mechanism(s) by which HO-1
confers protection against inflammation remains poorly un-
derstood, but more recently its products have emerged as the
potential mechanisms of action. CO and the bile pigments
biliverdin and bilirubin when administered exogenously may
exert potent cytoprotective effects. Moreover, they exert
their effects via distinctly different modes of action. For ex-
ample, CO has effects on vasomotor tone, increasing organ
perfusion after transplantation, whereas biliverdin does not
(34). Biliverdin prevented the up-regulation of adhesion
molecules and infiltrating leukocytes, whereas CO did not
(35). In two recent studies of acute intestinal inflammation
induced by dextran sodium sulfate in mice, HO-1 induction
reduced mucosal injury (29, 36). In contrast to our findings,
biliverdin recapitulated the protective effect of HO-1 induc-
tion in vivo, whereas CO did not (29). In our study, al-
though CO and pharmacologic HO-1 inducers alter IFN- 
signaling in murine macrophages, biliverdin does not (not de-
picted). These results suggest that the products of the HO-1
pathway impart antiinflammatory effects via different modes
of action. Furthermore, HO-1 may subserve different func-
tions in acute versus chronic models of inflammation. Finally,
we hypothesize that HO-1 may have a cytoprotective role
independent of its two major metabolic byproducts, CO and
biliverdin. Other possibilities include that ferritin expression
resulting from iron produced through HO-1 mediates pro-
tective effects (37). Alternatively, perhaps endogenously pro-
duced CO directs additional protective mechanisms over that
administered exogenously.
Collectively, these results show that CO alters IFN- 
signaling, suggesting that CO and HO-1 deviate an immune
response from a Th1 profile toward an antiinflammatory re-
sponse (Fig. 9). In Th1-mediated chronic mucosal inflam-
mation, IFN-  is a central mediator through induction of
IRF-8 and IL-12 p40 as well as through direct inhibition of
HO-1. Exogenous CO or HO-1 induction, likely through
inhibition of IRF-8, reverses the mucosal inflammatory pro-
cess. This concept is supported by a recent study (38) in
which hmox /  splenocytes were found to express increased
amounts of Th1 cytokines. This Th1 phenotype shift in
hmox /  mice may be attributable to lack of appropriate
control of IFN-  signaling through the HO-1 pathway. An-
other prediction of this model that requires testing is that
IFN-  blockade in IL-10 /  mice should be associated with
induction of HO-1. Not surprisingly, antibodies against
IFN-  ameliorate Th1-mediated murine colitis (39) and
may be an effective therapy in human CD (40).
This study may have important implications in human
IBD. First, therapeutic strategies designed to induce HO-1
may eliminate toxicity concerns associated with direct ad-
ministration of CO. Future experiments will further charac-
terize metabolic products and enzymes in the HO-1 path-
way as well as HO-1–inducing agents for immunologic
actions in IBD models. Furthermore, we had initially
pursued this line of investigation to study mechanisms of an
important epidemiological observation in human IBD:
Cigarette smoking is protective in UC (41). The “active”
immunomodulatory component(s) in cigarette smoke that
may explain this phenomenon remains ill defined. Cigarette
smoke is a complex mix of more than 500 characterized
compounds, each of which may exert independent immu-
nologic effects. Despite this complexity, immunologic and
clinical studies to address this issue in IBD have virtually all
focused on nicotine. Therapeutic trial experience in UC pa-
tients treated with nicotine gum and transdermal nicotine
has been inconclusive (42, 43). Interestingly, two recent re-
ports demonstrated that cigarette smoke suppresses Th1 cy-
tokines and enhances the production of IL-4 by human den-
dritic cell–primed T cells (44, 45). Based on our current
findings, the immunomodulatory effects of cigarette smoke
may in part be explained by CO (46). Blood carboxyhemo-
globin level, a measure of systemic exposure to CO, has
been reported to range from 1 to 18% in active smokers (47).
The association between cigarette smoking, carboxyhemo-
globin levels, and disease activity in patients with IBD war-
rants further investigation.
In conclusion, we demonstrate that CO administration
ameliorates established chronic mucosal inflammation in an
immunologic model of IBD. In Th1-mediated inflammatory
responses, CO alters IFN-  signaling in macrophages, result-
ing in decreased IRF-8 and IL-12 p40 expression. Immuno-
logic and therapeutic effects of CO are dependent on HO-1.
We have focused this analysis on how CO may alter macro-
phage activation, but CO may affect chronic inflammation
Figure 9. Model for the regulation of chronic intestinal inflammation 
by CO and HO-1. During chronic inflammation upon exposure to enteric 
bacteria and IFN- , intestinal macrophages secrete IL-12 p40. CO antago-
nizes this synergism through inhibition of IRF-8. IFN-  also inhibits both 
basal and LPS-induced HO-1 expression, and CO abrogates this inhibitory 
effect. Therefore, HO-1 acts downstream of CO to ameliorate Th1-mediated 
chronic intestinal inflammation.JEM VOL. 202, December 19, 2005 1711
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at many levels, including inhibiting T cell proliferation (48),
decreasing epithelial cell apoptosis (36), altering cell adhesion
and trafficking (49), and increasing intestinal blood flow
(50). Elucidation of these phenomena is likely to clarify the
pathogenesis of human IBD and may form the basis for new
therapeutic approaches.
MATERIALS AND METHODS
Mice. Male C57/Bl6, IL-10 /  and inos /  mice were obtained from The
Jackson Laboratory, and mkk3 /  and hmox /  mice were generated by R.
Flavell (Yale University School of Medicine, New Haven, CT) and S. Yet
(Harvard Medical School, Boston, MA), respectively. All wild-type and ge-
netically deficient mice used in this study were on the C57/Bl6 background
and matched for age and sex in all experiments. IL-10 /  mice were fed a
chow mixed with 200 ppm piroxicam (Sigma-Aldrich) for 5 d as indicated
in Results. Pelleted diets were prepared by Dyets, Inc. All animals were
housed in accordance with guidelines from the American Association for
Laboratory Animal Care and Research Protocols and were approved by the
Institutional Animal Care and Use Committee of the University of Pitts-
burgh. At the end of the study period, animals were killed using excess CO2
inhalation. Immediately afterward, blood by cardiac puncture (carboxyhe-
moglobin determination), spleens, intestinal tissue samples, and femurs were
collected. BM-derived macrophages and splenocytes were cultured as de-
scribed previously (26).
CO exposure. Mice or macrophages were exposed to compressed air or
CO at a concentration of 250 ppm as described previously (13). In brief, CO
at a concentration of 1% (10,000 ppm) in compressed air was mixed with
compressed air before being delivered into the exposure chamber. Flow into
animal chamber was maintained at rate of 12 liters/min and into the cell cul-
ture chamber at a rate of 2 liters/min. The cell culture chamber was humidi-
fied and maintained at 37 C. A CO analyzer (Interscan) was used to measure
CO levels continuously in the chambers. Cardiac blood samples (0.2 ml) were
taken immediately after the mice were killed to measure carboxyhemoglobin
using a hemoximeter (OSM3; Radiometer Copenhagen).
Pharmacologic inhibition and induction of HO-1. SnPP, hemin,
and CoPP (Frontier Scientific Porphyrin Products) were dissolved in so-
dium hydroxide, and the final pH of 7.4 was achieved by adding hydro-
chloric acid and further dilution with PBS. Because of light sensitivity,
SnPP, CoPP, and hemin were prepared in dim light, light protected, and
freshly made before injection.
Cytokine ELISAs. Murine IL-12 p40, IL-12 p70, IL-10, and TNF im-
munoassay kits (R&D Systems) and IL-23 (eBioscience) were used accord-
ing to the manufacturers’ instructions.
Western blot analysis. Western blot analyses were performed on nuclear
or whole cell extracts as noted in Results (Figs. 3–8) and described previ-
ously (26). Anti–IRF-1, anti–IRF-2, anti–IRF-4, anti–IRF-8, anti–STAT-1,
or anti–STAT-3 antibodies were from Santa Cruz Biotechnology, Inc., and
anti–HO-1 was from StressGen Biotechnologies.
IRF-8 retroviral transduction. For retroviral transduction, we used a
derivative of the Moloney murine leukemia virus vector pMMP412 (pro-
vided by H. Xiong, Mount Sinai School of Medicine, New York, NY; ref-
erence 28). To prepare pseudotyped virus, human 293 EbnaT cells were
seeded at a density of 4   106 cells in a 10-cm dish. The next day, cells
were transfected using Superfect (QIAGEN) with a mixture of 2.5  g of
plasmid pMD.G encoding vesicular stomatitis virus G protein, 7.5  g of
plasmid pMD.OGP encoding gag-pol, and 10  g of the IRF-8 retroviral
expression construct. 48 h after transfection, the viral supernatant was col-
lected, centrifuged at 1,500 rpm, and used to infect adherent BM-derived
macrophages in the presence of 4  g/ml polybrene for 6 h. 48 h after infec-
tion, macrophages were seeded in 24-well plates at 106 cells/ml, stimulated
with LPS or LPS and IFN- , and incubated for 24 h in the absence or pres-
ence of 250 ppm CO.
Nitrite determination. Nitrite concentration, a measure of NO synthe-
sis, was assayed by a standard Griess reaction adapted to a microplate system
as described previously (51). NaNO2 was used as a standard, and the data are
presented as a concentration of nitrite.
RNA extraction and real-time RT-PCR analysis. Total RNA was
isolated using TRIZOL reagent (Life Technologies). cDNA was derived
from 1  g total RNA by RT using an RT system (Promega). Real-time
RT-PCR was performed on RT products with specific primers.
Fluorophore-labeled LUX primers (52) and their unlabeled counter-
parts were purchased from Invitrogen. LUX primers were designed using a
software program (LUX Designer). LUX primers were designed to produce
amplicons ranging in size between 69 and 145 basepairs. Primer pairs for IL-
12 p40 and GAPDH were selected to span an intron. The primer sequences
for IL-12 p40 are: LUX: 5 -GAACTTGTCAAAGGCTTCATCTG-
CAAG5TC and its unlabeled counterpart: 5 -GGAAGCACGGCAGCA-
GAATA; for GAPDH: LUX: 5 -GACATACAGGCCGGTGCTGAG-
TATG5C and its unlabeled counterpart: 5 -GCGGAGATGATGACCC-
GTTT. Plots of fluorescence versus PCR cycle were generated by the ABI
PRISM 7700 SDS software. Each 25- l PCR reaction mix contained 2  l
cDNA, 1  l of each gene-specific primer, and 12.5  l 2X Platinum Quan-
titative PCR SuperMix-UDG (Invitrogen), 1  l 1X ROX reference dye,
and 7.5  l DEPC-treated water. Reactions were incubated at 50 C for 2
min, 95 C for 2 min, and then cycled (45 times) at 95 C for 15 s and 60 C
for 30 s. Quantitation of IL-12 p40 mRNA was expressed as relative fold-
increase in transcript level with respect to unstimulated cells. Real-time
RT-PCR for iNOS and HO-1 were performed as described previously
(53).
Transient transfections. J774 murine macrophages were transiently trans-
fected using SuperFect Transfection Reagent (QIAGEN) by the described
protocol with modifications. For each transfection, 2.5  g of plasmid were
mixed with 100  l DMEM (without serum and antibiotics) and 10  l of Su-
perFect reagent. The mixture was incubated at room temperature for 10 min,
and then 600  l DMEM complete medium was added and immediately
placed onto the cells in six-well plates. After incubation for 3–4 h at 37 C, the
cells were washed with PBS and split equally into two plates. 12–16 h later,
one six-well plate was treated with CO. Cells were either unactivated or acti-
vated with 1  g/ml LPS, 10 ng/ml IFN- , or both. 16–18 h after activation,
the cells were harvested by using 1X Reporter Lysis Buffer (Promega). Lu-
ciferase activity was determined from 20  l of cell extract as described previ-
ously (15). Cells were cotransfected with a constitutively active HSP pro-
moter that expresses  -galactosidase to monitor transfection efficiency.
Intestinal tissue explant cultures. Sections of the transverse colon from
individual mice were washed with PBS to remove fecal contents, shaken at
280 rpm at room temperature for 30 min in RPMI 1640 plus 50  g/ml
gentamicin, and cut into small fragments. Tissue fragments (0.5 g dry
weight) were incubated in 1.0 ml RPMI 1640 supplemented with 50  g/
ml gentamicin, 100 U/ml penicillin, 100  g/ml streptomycin, 0.25  g/ml
fungizone (GIBCO BRL), and 5% heat-inactivated fetal calf serum. Tissue
fragment supernatants were collected after 24 h for cytokine ELISAs.
Histology. Colons were removed after mice were killed and rinsed with
cold PBS to remove fecal material. Tissue sections were fixed in 10% buff-
ered formalin and embedded in paraffin. 5- m-thick sections were stained
with hematoxylin and eosin. Colitis scores (0–4) were determined by a staff
pathologist who was blinded to the experimental protocol using the criteria
reported by Berg et al. (22). 20 separate microscopic fields (magnification ofCARBON MONOXIDE AMELIORATES CHRONIC MURINE COLITIS | Hegazi et al. 1712
100) were evaluated for each mouse by a pathologist (A.R. Sepulveda)
blinded to the treatment groups.
Data analysis. Statistical analysis was performed using Student’s t test. A
probability level of P   0.05 was considered statistically significant.
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